<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233606</url>
  </required_header>
  <id_info>
    <org_study_id>20-0206</org_study_id>
    <nct_id>NCT04233606</nct_id>
  </id_info>
  <brief_title>Influence of Osmotic Stimulation of Vasopressin on Autonomic Function</brief_title>
  <official_title>Influence of Osmotic Stimulation of Vasopressin on Autonomic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Greensboro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Greensboro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regulation of total body water that defines human hydration status is a complex and
      dynamic process. Current methods of assessing hydration status (e.g. hematologic and urinary
      analyses) lack the ability to track changes in hydration status in real-time due to
      whole-body homeostatic physiologic processes required to maintain central pressure and
      cardiovascular function. This project will address this problem by assessing the relationship
      between autonomic function (measured using heart rate variability), a brain-derived process
      that regulates cardiovascular function, and changes in the hydration-mediated hormone
      vasopressin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will complete two trials under two different hydration states: isovolemic increase in plasma osmolality and isovolemic control (maintain normal plasma osmolality)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in autonomic function</measure>
    <time_frame>0, 15, 30, 45, 60, 75, 90, 105, 120 minutes of saline infusion period</time_frame>
    <description>Changes in parasympathetic and sympathetic tone as measured by heart rate variability</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Water Stress</condition>
  <condition>Body Water Dehydration</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be infused with normal (0.9% NaCL) saline for a 120 minute period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be infused with hypertonic (3% NaCL) saline for a 120 minute period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
    <description>Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin</description>
    <arm_group_label>Hypertonic Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Infusion of normal saline to inhibit the secretion of the hormone vasopressin</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females between the ages of 18 - 35

        Exclusion Criteria:

          -  1) evidence of clinically relevant diseases that may alter body water regulation
             (e.g., diabetes, kidney disease, metabolic disorders, cardiovascular disease, and
             other potential fluid balance covariates such as habitual use of non-steroidal
             anti-inflammatory drugs or serotonin reuptake inhibitors,

             2) previous surgery on the digestive tract that may impair the body's ability to
             normally regulate body water,

             3) regular drug treatment within the previous 15 days,

             4) actively attempting to gain or lose body weight,

             5) For female participants, testing will take place during the early follicular phase
             of their menstrual cycle (days 1-8) to maintain consistency in the hydration status
             measures as total body water fluctuates over the course of the menstrual cycle.
             Females who are currently using contraceptives (e.g., IUD) that limit the number of
             menstrual cycles occurring in a given year will be excluded from this study to ensure
             accuracy in the testing periods for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of North Carolina at Greensboro</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Greensboro</investigator_affiliation>
    <investigator_full_name>William Adams</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Vasopressin</keyword>
  <keyword>Heart Rate Variability</keyword>
  <keyword>Cardiovascular Function</keyword>
  <keyword>Autonomic Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

